Evicenter
MarkdownMedical informationP&T meetings
Cytisinicline

Smoking cessation

Last updated
83 sources

Section 4 of 6

Clinical evidence

251 evidence topics · 39 sources

Study summaries

ORCA-2

Objective
Location and study date
Study design
Eligibility criteria
Smoking eligibility threshold
CharacteristicQuoted value
Minimum cigarettes per day“10”View highlighted excerpt for this quote
Treatment
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Primary abstinence endpoint
CharacteristicQuoted value
Verification method“biochemically verified”
Primary assessment period“last 4 weeks of treatment”
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Primary analysis population and multiplicity
CharacteristicQuoted value
Analysis of all randomized participants: multiplicity adjustment“Hochberg procedure”View highlighted excerpt for this quote
Results
Participant disposition
Trial completion
CharacteristicQuoted value
Participants completing follow-up“618 (76.3%)”View highlighted excerpt for this quote
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes
Safety results
Study limitations
Summary

The comparator was placebo rather than another cessation medication. The primary endpoint assessed abstinence near the end of treatment; follow-up extended to week 24. The trial therefore does not establish comparative effectiveness against active medication or durability beyond 24 weeks.

ORCA-3

Objective
Location and study date
Study design
Eligibility criteria
Smoking eligibility threshold
CharacteristicQuoted value
Minimum cigarettes smoked daily“10”View highlighted excerpt for this quote
Treatment
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size and statistical power
Description of analysis sets
Primary analysis and multiplicity
Results
Participant disposition
Completion at week 24
CharacteristicQuoted value
Participants completing the trial“628”View highlighted excerpt for this quote
Completion percentage“79.3%”View highlighted excerpt for this quote
Baseline characteristics
Baseline age and sex
Efficacy results
Health-related quality of life and patient-reported outcomes
Change in smoking-urge score at week 6
CharacteristicQuoted value
Cytisinicline, mean change in points“−15.2”View highlighted excerpt for this quote
Placebo, mean change in points“−12.0”View highlighted excerpt for this quote
Safety results
Study limitations
Summary

The study replicated placebo-controlled findings but did not compare cytisinicline with an active cessation medication. Of 792 randomized participants, 628 completed the trial. Follow-up through week 24 does not establish longer-term abstinence or safety.

ORCA-OL

Objective
Location and study date
U.S. study sites
CharacteristicQuoted value
Number of U.S. sites“29”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary safety endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Treated participants
CharacteristicQuoted value
Treated sample“475”
Description of analysis sets
Results
Participant disposition
Exposure duration
CharacteristicQuoted value
Participants exposed for at least 24 weeks, number and percentage“392 (82.5)”
Participants exposed for at least 48 weeks, number and percentage“319 (67.2)”
Participants exposed for at least 51 weeks, number and percentage“281 (59.2)”
Baseline characteristics
Baseline age and sex
CharacteristicQuoted value
Median age, years“55”
Female participants, number and percentage“275 (57.9)”
Efficacy results

Not applicable.

Health-related quality of life and patient-reported outcomes
Safety results
Study limitations
Summary

This open-label study had no concurrent comparator. It enrolled participants previously treated in the ORCA program, rather than a newly recruited randomized population. Exposure declined from 475 treated participants to 281 with at least 51 weeks of treatment. The exit survey was voluntary.

ORCA-1

Objective
Location and study date
Study design
Eligibility criteria
Cigarette-use eligibility
CharacteristicQuoted value
Baseline daily cigarette threshold“>10”View highlighted excerpt for this quote
Treatment
Cytisinicline dose levels
Study outcomes
Rationale for using percentage of expected cigarettes smoked as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized participants
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline age and smoking
Efficacy results
Cytisinicline 3 mg three times daily versus placebo
OutcomeCytisiniclinePlaceboP value
Four-week abstinence“50%”“10%”“p < 0.001”
Continuous abstinence, weeks 5–8“30%”“8%”“p = 0.005”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary

The primary endpoint measured cigarette reduction, not sustained smoking cessation. The table’s four-week abstinence label refers to seven-day point-prevalence abstinence at the end of treatment, not four weeks of continuous abstinence. Continuous abstinence was evaluated separately during weeks 5–8.

ORCA-V1

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Dose schedule
Study outcomes
Rationale for using continuous e-cigarette abstinence as the primary endpoint
Primary endpoint assessment
CharacteristicQuoted value
Continuous vaping-abstinence interval, weeks“9-12”View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Trial completion
CharacteristicQuoted value
Participants completing follow-up“131”View highlighted excerpt for this quote
Baseline characteristics
Baseline age
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse-event discontinuations
CharacteristicQuoted value
Participants discontinuing cytisinicline because of an adverse event“4”View highlighted excerpt for this quote
Study limitations
Summary

This study enrolled adults who vaped but did not currently smoke cigarettes. It therefore provides supporting evidence for vaping cessation rather than a direct estimate of smoking-cessation efficacy. The investigators called for a larger trial with longer follow-up.

ISRCTN37568749

Objective
Location and study date

No evidence found.

Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment
CharacteristicQuoted value
Randomized participants“740”View highlighted excerpt for this quote
Participants per treatment group“370”View highlighted excerpt for this quote
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Gastrointestinal adverse events
CharacteristicQuoted value
Absolute excess with cytisine, percentage points“5.7”View highlighted excerpt for this quote
Study limitations
Summary

This was a single-center trial with minimal counseling and a 25-day cytisine regimen. Its results do not directly test the 6-week or 12-week, 3 mg three-times-daily regimen evaluated in ORCA-2.

ACTRN12610000590066

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Treatment duration
CharacteristicQuoted value
Cytisine course, days“25”
Nicotine replacement therapy“8 weeks”
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Primary outcome
CharacteristicQuoted value
Ascertainment“self-reported”
Continuous-abstinence assessment“1 month”
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized participants
CharacteristicQuoted value
Total randomized“1310”
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Participants reporting adverse events
CharacteristicQuoted value
Cytisine“204”
Nicotine replacement therapy“134”
Study limitations
Summary

Treatment was open-label and the primary outcome was self-reported abstinence at one month. Cytisine and nicotine replacement therapy were given for different durations. These features limit blinding and comparability with trials using biochemical verification as the primary outcome.

NCT02957786

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Treatment duration
CharacteristicQuoted value
Cytisine and varenicline courses“12 weeks”
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Primary outcome timing
CharacteristicQuoted value
Verified continuous-abstinence assessment“6 months”
Statistical analysis description
Number of participants (Planned and analyzed)
Planned and actual enrollment
CharacteristicQuoted value
Planned participants“2140”
Randomized participants“679”
Description of analysis sets
Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Reported adverse events
CharacteristicQuoted value
Cytisine events“313”
Varenicline events“509”
Study limitations
Summary

Enrollment was 679 participants compared with a planned 2,140. The open-label design and recruitment below target limit precision and leave potential reporting and performance bias. The population and 12-week cytisine regimen differ from other historical cytisine trials.

ACTRN12616001654448

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Primary outcome
CharacteristicQuoted value
Continuous-abstinence assessment“6 months”View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Noninferiority threshold
Results
Participant disposition
Follow-up completion
CharacteristicQuoted value
Participants completing follow-up“1108”View highlighted excerpt for this quote
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary

The primary analysis did not establish noninferiority. Cytisine was administered for 25 days and varenicline for 84 days, so the comparison combines differences in medication and duration. The trial was open-label.

ISRCTN43811467

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Primary assessment
CharacteristicQuoted value
Continuous-abstinence follow-up, months“6”View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results
Continuous abstinence at 6 months
CharacteristicQuoted value
Cytisine participants abstinent“401”View highlighted excerpt for this quote
Placebo participants abstinent“366”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Participants with serious adverse events
Study limitations
Summary

The study population had pulmonary tuberculosis, and both groups received brief behavioral support. The investigators did not support adding cytisine in this setting. Results should not be treated as a direct evaluation of the ORCA regimen in the general smoking population.

SMILE

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Primary outcome
CharacteristicQuoted value
Continuous-abstinence assessment“12 months”View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results
Biochemically verified continuous abstinence
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Participants reporting adverse events
Study limitations
Summary

This single-center trial enrolled current heavy smokers in lung-cancer screening. Its control was counseling alone rather than placebo tablets or an active cessation medication. Applicability to other smoking populations and comparative tolerability against active medication remain uncertain.

TCTR20180312001

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Primary endpoint
CharacteristicQuoted value
Continuous-abstinence assessment“week 48”View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Treatment groups
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary

The trial included 67 participants receiving cytisine and 65 receiving placebo. The week-48 relative-risk confidence interval included no difference (relative risk 2.41; 95% confidence interval 0.80–7.35; P = 0.102). The small groups limit precision and assessment of uncommon harms.

Cytisine versus nortriptyline

Objective
Location and study date

No evidence found.

Study design
Eligibility criteria
Eligibility thresholds
CharacteristicQuoted value
Minimum age, years“20”
Minimum cigarettes per day“10”
Treatment
Treatment courses
CharacteristicQuoted value
Cytisine“25-day”
Nortriptyline“12-week”
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized participants
CharacteristicQuoted value
Total“1086”
Cytisine“540”
Nortriptyline“546”
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary

The observed relative-risk confidence interval, 0.91–1.81, includes no difference. The nonsignificant comparison does not by itself establish equivalence. Cytisine and nortriptyline were administered for different durations.

Cytisine versus varenicline in primary care

Objective

No evidence found.

Location and study date

No evidence found.

Study design

No evidence found.

Eligibility criteria

No evidence found.

Treatment

No evidence found.

Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint

No evidence found.

Statistical analysis description
Number of participants (Planned and analyzed)

No evidence found.

Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations

No evidence found.

NCT04286295

Objective
Location and study date

No evidence found.

Study design
Eligibility criteria
Treatment
Treatment course
CharacteristicQuoted value
Cytisine or combination nicotine replacement therapy“25 days”View highlighted excerpt for this quote
Study outcomes
Rationale for using recruitment and treatment adherence as the primary feasibility endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Recruitment
CharacteristicQuoted value
Recruited participants“13”View highlighted excerpt for this quote
Description of analysis sets

No evidence found.

Results
Participant disposition
Baseline characteristics

No evidence found.

Efficacy results
Participants abstinent at day 25
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary

This pilot recruited 13 participants and nine completed follow-up. It was designed to evaluate recruitment and adherence, not to provide a definitive comparative efficacy estimate. Its end-of-treatment cessation findings are therefore exploratory.

RISP

Objective

No evidence found.

Location and study date

No evidence found.

Study design

No evidence found.

Eligibility criteria

No evidence found.

Treatment

No evidence found.

Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint

No evidence found.

Statistical analysis description
Number of participants (Planned and analyzed)

No evidence found.

Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations

No evidence found.

CITISILONG

Objective
Location and study date
Study design
Eligibility criteria
Adult eligibility threshold
CharacteristicQuoted value
Minimum age, years“18”
Treatment
Planned cytisine durations
CharacteristicQuoted value
Standard course, days“25”
Extended course, days“50”
Longest course, days“75”
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned statistical design
CharacteristicQuoted value
Target participants“402”
Power“80%”
Anticipated losses“21%”
Description of analysis sets
Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary

The report contains a protocol, not observed cessation or safety results. Planned comparisons are open-label and use 25-, 50-, and 75-day courses. The clinically evaluable analysis population may differ from all randomized participants.

Forty-day cytisine regimen

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using biochemically confirmed smoking abstinence as a study endpoint
Abstinence assessment
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition

No evidence found.

Baseline characteristics
Cytisine group at baseline
Efficacy results
Biochemically confirmed smoking abstinence
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Cytisine adverse events
Study limitations
Summary

Allocation was not randomized, and there was no placebo group or direct comparison with the standard 25-day cytisine regimen. The observed differences cannot establish that extending treatment to 40 days caused improved outcomes.

CITOSP

Objective
Location and study date
Enrollment years
CharacteristicQuoted value
First year“2021”
Last year“2023”
Study design
Eligibility criteria
Treatment
Cytisine administration
CharacteristicQuoted value
Oral cytisine unit dose“1.5 mg”
Treatment duration“25 days”
Study outcomes
Rationale for using adverse drug reactions as the primary safety endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Enrolled participants
CharacteristicQuoted value
Cohort size“36”
Description of analysis sets
Results
Participant disposition
Study completion
CharacteristicQuoted value
Participants completing the study“22 (61.1%)”
Baseline characteristics
Baseline sex
CharacteristicQuoted value
Male participants“83.3%”
Efficacy results
Self-reported seven-day point-prevalence abstinence
CharacteristicQuoted value
At 3 months“50%”
At 6 months“47%”
At 12 months“36%”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary

The evidence comes from a prospective observational cohort of 36 hospitalized smokers with cardiovascular disease. Its small size and lack of randomized comparison limit causal interpretation and assessment of uncommon cardiovascular harms. The reported longitudinal cessation percentages are self-reported outcomes.

Retrospective comparative-effectiveness cohort

Objective
Location and study date
Study design
Eligibility criteria
Adult eligibility
CharacteristicQuoted value
Minimum age, years“18”
Treatment
Medication groups
Study outcomes
Rationale for using self-reported smoking abstinence as a study endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Analyzed participants
CharacteristicQuoted value
Total cohort“113”
Description of analysis sets
Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results
Overall cessation
CharacteristicQuoted value
Participants classified as quitters“67”
Participants classified as non-quitters“46”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary

Treatment selection reflected routine practice rather than randomization, and multivariable modeling was not performed. The association between adherence and cessation does not establish a causal medication effect or an adjusted comparative treatment effect.

DESTINA

Objective

No evidence found.

Location and study date

No evidence found.

Study design

No evidence found.

Eligibility criteria

No evidence found.

Treatment

No evidence found.

Study outcomes
Rationale for using patient satisfaction and tolerability as the study outcomes

No evidence found.

Statistical analysis description
Number of participants (Planned and analyzed)

No evidence found.

Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes
Safety results

No evidence found.

Study limitations

No evidence found.

Placebo-controlled trial in workers

Objective
Location and study date

No evidence found.

Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using self-reported continuous abstinence as a study endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized participants
CharacteristicQuoted value
Total“171”
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results
Health-related quality of life and patient-reported outcomes
Safety results

No evidence found.

Study limitations
Summary

Abstinence was self-reported. The study enrolled men working in mining, limiting direct applicability to broader clinical populations. It evaluated a 25-day regimen rather than the longer ORCA regimens.

Matching-adjusted indirect comparison

Objective
Location and study date

Not applicable.

Study design
Eligibility criteria
Treatment
Treatment exposure
CharacteristicQuoted value
Cytisinicline course“12 weeks”
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Abstinence assessment intervals
CharacteristicQuoted value
End of treatment“Weeks 9-12”
Longer follow-up“Weeks 9-24”
Statistical analysis description
Number of participants (Planned and analyzed)
Contributing cytisinicline trials
CharacteristicQuoted value
Trials pooled“ORCA-2 and ORCA-3”
Description of analysis sets
Results
Participant disposition

Not applicable.

Baseline characteristics

No evidence found.

Efficacy results
Adjusted continuous-abstinence estimates
AssessmentQuoted estimate
Continuous abstinence, weeks 9–12“adjusted OR, 1.33; 95% CI, 0.86-2.05”
Continuous abstinence, weeks 9–24“adjusted OR, 1.95; 95% CI, 1.13-3.34”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adjusted nausea estimate
Study limitations
Summary

This is an indirect comparison, not a randomized head-to-head trial. Weighting cannot remove confounding from unmeasured differences between trials. The weeks 9–12 odds-ratio confidence interval includes no difference, while the weeks 9–24 interval does not. These estimates should not be interpreted as head-to-head evidence.

Phase I dose-escalation study

Objective

No evidence found.

Location and study date

No evidence found.

Study design

No evidence found.

Eligibility criteria

No evidence found.

Treatment

No evidence found.

Study outcomes
Rationale for using tolerability and safety as the primary endpoints

No evidence found.

Statistical analysis description
Number of participants (Planned and analyzed)

No evidence found.

Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

Not applicable.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations

No evidence found.

Single-dose pharmacokinetic study

Objective
Location and study date

No evidence found.

Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using plasma and urinary cytisine concentrations as the pharmacokinetic endpoints

Not applicable.

Statistical analysis description
Number of participants (Planned and analyzed)

No evidence found.

Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary

The study characterized a single dose in healthy smokers. It does not establish smoking-cessation efficacy or the safety of repeated administration for 6 or 12 weeks.

ACTRN12613000002785

Objective
Location and study date

No evidence found.

Study design
Eligibility criteria
Treatment
Regimen duration
Study outcomes
Rationale for using plasma cytisine concentrations as the pharmacokinetic endpoint

Not applicable.

Statistical analysis description
Number of participants (Planned and analyzed)
Participants
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary

The pharmacokinetic study included 10 healthy adult smokers and used the standard 25-day regimen. It provides evidence of accumulation but cannot establish clinical cessation efficacy or detect uncommon harms.

Ascending-dose pharmacokinetic study

Objective

No evidence found.

Location and study date

No evidence found.

Study design

No evidence found.

Eligibility criteria

No evidence found.

Treatment

No evidence found.

Study outcomes
Rationale for using cytisine pharmacokinetics as the primary endpoint

Not applicable.

Statistical analysis description
Number of participants (Planned and analyzed)

No evidence found.

Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

Not applicable.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations

No evidence found.